Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 10/20 | 0.58 |
| ▸ | CYP11B1 | P15538 | 8/20 | 0.53 |
| ▸ | CYP11B2 | P19099 | 7/20 | 0.53 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.50 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1171091 | 0.89 | HRH3 (0.49) | CYP19A1CYP11B1CYP11B2TBXAS1MEN1 | |
| SCHEMBL1552675 | 0.74 | CYP19A1 (1.00) | CYP19A1CYP11B1CYP11B2TBXAS1CYP17A1 | |
| SCHEMBL7297515 | 0.69 | CYP11B1 (1.00) | CYP19A1CYP11B1CYP11B2CYP17A1 | |
| SCHEMBL29107867 | 0.67 | CYP11B1 (0.60) | CYP19A1CYP11B1CYP11B2TBXAS1CYP17A1 | |
| SCHEMBL5041356 | 0.65 | NPC1 (0.46) | — | |
| SCHEMBL11159001 | 0.64 | CYP11B1 (0.53) | CYP19A1CYP11B1CYP11B2TBXAS1CYP17A1 | |
| SCHEMBL9219749 | 0.64 | CYP11B1 (0.54) | CYP19A1CYP11B1CYP11B2TBXAS1CYP17A1 | |
| SCHEMBL10492343 | 0.63 | CYP11B1 (0.49) | CYP19A1CYP11B1CYP11B2TBXAS1 | |
| SCHEMBL1170919 | 0.63 | ALOX15 (0.39) | MEN1KMT2A | |
| SCHEMBL1171095 | 0.63 | HTR1A (0.38) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110034434-A1 | PRODRUGS OF FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE | SEPRACOR INC. (US) | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034434-A1 | PRODRUGS OF FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE | DDO, DAO, AOC1 | CYP19A1 834/4885CYP11B1 714/4885CYP11B2 667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.